A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine RefractoryBRAFp.V600E-Mutated Differentiated Thyroid Cancer

发表于半小时前

期刊：Clinical Cancer Research

文献作者：Sophie Leboulleux; Christine Do Cao; Slimane Zerdoud; Marie Attard; Claire Bournaud; Ludovic Lacroix; Danielle Benisvy; David Taieb; Stéphane Bardet; Marie Terroir-Cassou-Mounat; Nadège Anizan; Emilie Bouvier-Morel; Livia Lamartina; Georges Lion; Sarah Betrian; Christophe Sajous; Aurélie Schiazza; Marie-Eve Garcia; Renaud Ciappuccini; Martin Schlumberger; Abir Al Ghuzlan; Yann Godbert; Isabelle Borget

出版日期：2023-7-5

DOI号：10.1158/1078-0432.ccr-23-0046

下载链接：https://aacrjournals.org/clincan ... 596/ccr-23-0046.pdf

文献链接：https://doi.org/10.1158/1078-0432.ccr-23-0046

当前文献来源于 American Association for Cancer Research (AACR)。

备注信息：

发表于半小时前

: 当前求助处于待确认状态,请尽快下载
如果48小时后该求助仍未采纳，系统将自动采纳。

[AACR] A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine RefractoryBRAFp.V600E-Mutated Differentiated Thyroid Cancer

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[AACR] A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine RefractoryBRAFp.V600E-Mutated Differentiated Thyroid Cancer 一键复制